Contact
searchSearch
HMP Global
Login

Pancreatic Cancer Resource Center

FDA Approval
FDA Approves Irinotecan Liposome for First-Line Metastatic Pancreatic Adenocarcinoma
02/13/2024
Allison Casey
The US Food and Drug Association has granted approval to irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma in the first-line setting.
The US Food and Drug Association has granted approval to irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma in the first-line setting.
The US Food and Drug Association...
02/13/2024
Oncology
From Oncology
Quiz
Quiz: Cost of Biosimilar Neutropenia Prophylaxis for Pancreatic Cancer
03/10/2022
True or False: Conversion to biosimilar pegfilgrastim-cbqv for chemotherapy-induced neutropenia and febrile neutropenia prophylaxis can generate cost-savings for patients with metastatic pancreatic cancer.
True or False: Conversion to biosimilar pegfilgrastim-cbqv for chemotherapy-induced neutropenia and febrile neutropenia prophylaxis can generate cost-savings for patients with metastatic pancreatic cancer.
True or False: Conversion to...
03/10/2022
Journal of Clinical Pathways
News
Conversion to Biosimilar Neutropenia Prophylaxis Generates Cost-Savings and Provides Access to Pancreatic Cancer Treatment
02/11/2022
Janelle Bradley
Conversion to biosimilar pegfilgrastim-cbqv for neutropenia prophylaxis can generate potential cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.
Conversion to biosimilar pegfilgrastim-cbqv for neutropenia prophylaxis can generate potential cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.
Conversion to biosimilar...
02/11/2022
Journal of Clinical Pathways
Quiz
Quiz: Educating Patients With Pancreatic Cancer About Treatment Options
02/10/2022
True or False: Patients with pancreatic cancer infrequently hear about treatment complications and alternatives, while frequently hearing about logistics and potential outcomes.
True or False: Patients with pancreatic cancer infrequently hear about treatment complications and alternatives, while frequently hearing about logistics and potential outcomes.
True or False: Patients with...
02/10/2022
Journal of Clinical Pathways
News
Study Identifies Areas for Improvement in Educating Patients With Pancreatic Cancer About Treatment Options
11/03/2021
Marta Rybczynski
Study identifies key elements of information clinicians need to communicate to patients with pancreatic cancer to help make informed decisions regarding preoperative therapy.
Study identifies key elements of information clinicians need to communicate to patients with pancreatic cancer to help make informed decisions regarding preoperative therapy.
Study identifies key elements of...
11/03/2021
Journal of Clinical Pathways
Real-World Outcomes of Recurrent vs De Novo Metastatic Pancreatic Cancer
Videos
Real-World Outcomes of Recurrent vs De Novo Metastatic Pancreatic Cancer
02/03/2021
Laura Miotke, MD, discusses data suggesting that patients with recurrent metastatic pancreatic adenocarcinoma have significantly better survival outcomes compared with those with de novo metastatic disease.
Laura Miotke, MD, discusses data suggesting that patients with recurrent metastatic pancreatic adenocarcinoma have significantly better survival outcomes compared with those with de novo metastatic disease.
Laura Miotke, MD, discusses data...
02/03/2021
Journal of Clinical Pathways
High Costs of Pancreatic Enzyme Replacement Therapy Barrier to Medicare Beneficiary Drug Access
Videos
High Costs of Pancreatic Enzyme Replacement Therapy Barrier to Medicare Beneficiary Drug Access
01/20/2021
Arjun Gupta, MD, discusses results from a study assessing out-of-pocket and total spending on pancreatic enzyme replacement therapy under Medicare Part D.
Arjun Gupta, MD, discusses results from a study assessing out-of-pocket and total spending on pancreatic enzyme replacement therapy under Medicare Part D.
Arjun Gupta, MD, discusses...
01/20/2021
Journal of Clinical Pathways
Quiz
Quiz: What Drives Health Care Costs for Patients With Pancreatic Cancer?
09/11/2020
09/11/2020
Journal of Clinical Pathways
News
Outpatient Services Drive Health Care Costs for Patients With Metastatic Pancreatic Cancer
09/10/2020
Study findings show health care costs for patients with metastatic pancreatic ductal adenocarcinoma who received treatment with nab-paclitaxel and gemcitabine or FOLFIRINOX are driven mostly by outpatient costs.
Study findings show health care costs for patients with metastatic pancreatic ductal adenocarcinoma who received treatment with nab-paclitaxel and gemcitabine or FOLFIRINOX are driven mostly by outpatient costs.
Study findings show health care...
09/10/2020
Journal of Clinical Pathways
AGA Updates Clinical Practice Guideline for Pancreatic Cancer Screening
Guideline Updates
AGA Updates Clinical Practice Guideline for Pancreatic Cancer Screening
06/29/2020
Individuals at high risk for pancreatic cancer should at minimum be considered for screening for the disease, according to a new clinical practice update from the American Gastroenterological Association
Individuals at high risk for pancreatic cancer should at minimum be considered for screening for the disease, according to a new clinical practice update from the American Gastroenterological Association
Individuals at high risk for...
06/29/2020
Journal of Clinical Pathways
Research in Review
Pancreatic Cancer Guidelines Do Not Cover Some Targetable Mutations
08/11/2017
Germline mutations in pancreatic cancer susceptibility genes are often identified in patients with pancreatic cancer without a known family history of cancer, according to a recent study. ----- Related...
Germline mutations in pancreatic cancer susceptibility genes are often identified in patients with pancreatic cancer without a known family history of cancer, according to a recent study. ----- Related...
...
08/11/2017
Journal of Clinical Pathways

Expert Insights

Real-World Outcomes of Recurrent vs De Novo Metastatic Pancreatic Cancer
Videos
Real-World Outcomes of Recurrent vs De Novo Metastatic Pancreatic Cancer
02/03/2021
Laura Miotke, MD, discusses data suggesting that patients with recurrent metastatic pancreatic adenocarcinoma have significantly better survival outcomes compared with those with de novo metastatic disease.
Laura Miotke, MD, discusses data suggesting that patients with recurrent metastatic pancreatic adenocarcinoma have significantly better survival outcomes compared with those with de novo metastatic disease.
Laura Miotke, MD, discusses data...
02/03/2021
Journal of Clinical Pathways
High Costs of Pancreatic Enzyme Replacement Therapy Barrier to Medicare Beneficiary Drug Access
Videos
High Costs of Pancreatic Enzyme Replacement Therapy Barrier to Medicare Beneficiary Drug Access
01/20/2021
Arjun Gupta, MD, discusses results from a study assessing out-of-pocket and total spending on pancreatic enzyme replacement therapy under Medicare Part D.
Arjun Gupta, MD, discusses results from a study assessing out-of-pocket and total spending on pancreatic enzyme replacement therapy under Medicare Part D.
Arjun Gupta, MD, discusses...
01/20/2021
Journal of Clinical Pathways
Houda Hachad, PharmD
Interview
FDA Highlights Risks Associated With DPD Deficiency, Advises Testing Before Treatment
03/26/2025
Houda Hachad, PharmD
This interview explores the US Food and Drug Administration’s (FDA) updated guidance on dihydropyrimidine dehydrogenase (DPD) deficiency and its implications for improving patient safety through pre-treatment DPYD testing before...
This interview explores the US Food and Drug Administration’s (FDA) updated guidance on dihydropyrimidine dehydrogenase (DPD) deficiency and its implications for improving patient safety through pre-treatment DPYD testing before...
This interview explores the US...
03/26/2025
Journal of Clinical Pathways
Upal Basu Roy, PhD, MPH
Interview
Project PRIORITY: Elevating the Patient Voice in EGFR-Positive NSCLC Care
03/24/2025
Upal Basu Roy, PhD, MPH
In this interview, Upal Basu Roy, PhD, MPH, shares how by centering on patient experiences, Project PRIORITY reveals critical disparities in access to diagnostics, treatment, and palliative care for patients with epidermal growth factor...
In this interview, Upal Basu Roy, PhD, MPH, shares how by centering on patient experiences, Project PRIORITY reveals critical disparities in access to diagnostics, treatment, and palliative care for patients with epidermal growth factor...
In this interview, Upal Basu...
03/24/2025
Journal of Clinical Pathways
Videos
Why Pathways Matter: Editorial Advisory Board Testimonials
03/24/2025
F. Randy Vogenberg, PhD, FASHP
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal...
03/24/2025
Journal of Clinical Pathways
Kohli Headshot
Interview
Strengthening Patient Pathways With BIS for Lymphedema Surveillance
03/24/2025
Manpreet Kohli, MD
In this interview, Manpreet Kohli, MD, discusses the incorporation of bioimpedance spectroscopy into NAPBC standards, the impact of early lymphedema detection on survivorship, and how clinicians can better support patient-centered care...
In this interview, Manpreet Kohli, MD, discusses the incorporation of bioimpedance spectroscopy into NAPBC standards, the impact of early lymphedema detection on survivorship, and how clinicians can better support patient-centered care...
In this interview, Manpreet...
03/24/2025
Journal of Clinical Pathways
Chelsea Renfro, PharmD
Interview
How Integrated Health System Pharmacies Enhance Treatment Adherence and Adverse Effect Management for CLL
03/21/2025
Houston Wyatt, PharmD; Chelsea E. Renfro, PharmD; Stephanie White, PharmD
This interview explores how integrated health system pharmacy services can improve medication adherence, persistence, and adverse effect management in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
This interview explores how integrated health system pharmacy services can improve medication adherence, persistence, and adverse effect management in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
This interview explores how...
03/21/2025
Journal of Clinical Pathways
Videos
Progress and Unmet Needs in Post-IO Treatment for Metastatic RCC
03/19/2025
Neil Shah, MD
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah...
03/19/2025
Journal of Clinical Pathways
Graf Headshot
Interview
The Future of Chronic Lymphocytic Leukemia Management with Targeted Therapies
03/17/2025
In this interview, an expert discusses the preclinical development and clinical impact of zanubrutinib in chronic lymphocytic leukemia, highlighting key findings from pivotal trials, comparisons with other therapies, and future research...
In this interview, an expert discusses the preclinical development and clinical impact of zanubrutinib in chronic lymphocytic leukemia, highlighting key findings from pivotal trials, comparisons with other therapies, and future research...
In this interview, an expert...
03/17/2025
Journal of Clinical Pathways
Oncology Innovations
Videos
Advancing Value-Based Oncology With the Predictable Cost of Care Working Group: Part 2
03/17/2025
Gordon Kuntz; Carole Tremonti, RN, MBA
In this episode of Oncology Innovations, experts discuss the Predictable Cost of Care Working Group’s efforts to develop a standardized model for assessing oncology treatment costs, highlighting insights from phase I, the goals of phase II,...
In this episode of Oncology Innovations, experts discuss the Predictable Cost of Care Working Group’s efforts to develop a standardized model for assessing oncology treatment costs, highlighting insights from phase I, the goals of phase II,...
In this episode of Oncology...
03/17/2025
Journal of Clinical Pathways
Brian S.
Interview
Key Advancements in Immunotherapy for Endometrial Cancer
03/13/2025
Brian M. Slomovitz, MD, MS
A guest expert discusses groundbreaking research on pembrolizumab in adjuvant treatment for endometrial cancer, highlighting the significant impact on reducing recurrence risk in patients with deficient mismatch repair and the need for...
A guest expert discusses groundbreaking research on pembrolizumab in adjuvant treatment for endometrial cancer, highlighting the significant impact on reducing recurrence risk in patients with deficient mismatch repair and the need for...
A guest expert discusses...
03/13/2025
Journal of Clinical Pathways
Brufsky Headshot
Interview
Transforming Metastatic Breast Cancer Care With AI and Real-World Evidence
03/11/2025
Adam Brufsky, MD, PhD
In this interview, Adam Brufsky, MD, PhD, discusses the evolving treatment landscape for hormone receptor-positive/HER2-negative metastatic breast cancer, the impact of CDK4/6 inhibitors, the role of genomic assays and artificial intelligence...
In this interview, Adam Brufsky, MD, PhD, discusses the evolving treatment landscape for hormone receptor-positive/HER2-negative metastatic breast cancer, the impact of CDK4/6 inhibitors, the role of genomic assays and artificial intelligence...
In this interview, Adam Brufsky,...
03/11/2025
Journal of Clinical Pathways

Newsfeed

FDA Approval
FDA Approves Irinotecan Liposome for First-Line Metastatic Pancreatic Adenocarcinoma
02/13/2024
Allison Casey
The US Food and Drug Association has granted approval to irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma in the first-line setting.
The US Food and Drug Association has granted approval to irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma in the first-line setting.
The US Food and Drug Association...
02/13/2024
Oncology
News
Conversion to Biosimilar Neutropenia Prophylaxis Generates Cost-Savings and Provides Access to Pancreatic Cancer Treatment
02/11/2022
Janelle Bradley
Conversion to biosimilar pegfilgrastim-cbqv for neutropenia prophylaxis can generate potential cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.
Conversion to biosimilar pegfilgrastim-cbqv for neutropenia prophylaxis can generate potential cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.
Conversion to biosimilar...
02/11/2022
Journal of Clinical Pathways
News
Study Identifies Areas for Improvement in Educating Patients With Pancreatic Cancer About Treatment Options
11/03/2021
Marta Rybczynski
Study identifies key elements of information clinicians need to communicate to patients with pancreatic cancer to help make informed decisions regarding preoperative therapy.
Study identifies key elements of information clinicians need to communicate to patients with pancreatic cancer to help make informed decisions regarding preoperative therapy.
Study identifies key elements of...
11/03/2021
Journal of Clinical Pathways
News
Outpatient Services Drive Health Care Costs for Patients With Metastatic Pancreatic Cancer
09/10/2020
Study findings show health care costs for patients with metastatic pancreatic ductal adenocarcinoma who received treatment with nab-paclitaxel and gemcitabine or FOLFIRINOX are driven mostly by outpatient costs.
Study findings show health care costs for patients with metastatic pancreatic ductal adenocarcinoma who received treatment with nab-paclitaxel and gemcitabine or FOLFIRINOX are driven mostly by outpatient costs.
Study findings show health care...
09/10/2020
Journal of Clinical Pathways
AGA Updates Clinical Practice Guideline for Pancreatic Cancer Screening
Guideline Updates
AGA Updates Clinical Practice Guideline for Pancreatic Cancer Screening
06/29/2020
Individuals at high risk for pancreatic cancer should at minimum be considered for screening for the disease, according to a new clinical practice update from the American Gastroenterological Association
Individuals at high risk for pancreatic cancer should at minimum be considered for screening for the disease, according to a new clinical practice update from the American Gastroenterological Association
Individuals at high risk for...
06/29/2020
Journal of Clinical Pathways
Conference Coverage
Delayed EGFR Testing in Early-Stage NSCLC Linked to Increased Health Care Utilization and Cost Burden
04/01/2025
Juliet Gallagher
Timely molecular testing is essential for guiding targeted treatment in patients with early-stage non-small cell lung cancer (eNSCLC), particularly those with EGFR mutations. Findings presented at the 2025 National Comprehensive Cancer...
Timely molecular testing is essential for guiding targeted treatment in patients with early-stage non-small cell lung cancer (eNSCLC), particularly those with EGFR mutations. Findings presented at the 2025 National Comprehensive Cancer...
Timely molecular testing is...
04/01/2025
Journal of Clinical Pathways
Conference Coverage
Study Explores Early Palliative Care Referral Patterns and Outcomes in SCLC
04/01/2025
Juliet Gallagher
At the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference, researchers presented findings from a retrospective study evaluating timing of palliative care referral and associated outcomes among patients with small cell lung...
At the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference, researchers presented findings from a retrospective study evaluating timing of palliative care referral and associated outcomes among patients with small cell lung...
At the 2025 National...
04/01/2025
Journal of Clinical Pathways
Conference Coverage
EHR-Embedded CDS Tool Enhances Specialty Drug Management in Oncology
03/28/2025
Juliet Gallagher
A retrospective study presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference evaluated how embedding a clinical decision support (CDS) tool within the electronic health record (EHR) can enhance specialty drug...
A retrospective study presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference evaluated how embedding a clinical decision support (CDS) tool within the electronic health record (EHR) can enhance specialty drug...
A retrospective study presented...
03/28/2025
Journal of Clinical Pathways
Conference Coverage
Patient-Centered Insights into Treatment Preferences for Locally Advanced and Metastatic NSCLC
03/28/2025
Juliet Gallagher
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the...
03/28/2025
Journal of Clinical Pathways
News
Academic Cancer Centers Improve Outcomes for Patients With Mantle Cell Lymphoma
03/18/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell...
03/18/2025
Journal of Clinical Pathways
News
Improving Health Care Access for Immigrants With Disabilities in North America
03/14/2025
Hannah Musick
Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...
Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...
Exploring the barriers and...
03/14/2025
Journal of Clinical Pathways
News
AI Revolutionizes Early Detection and Diagnosis of Gastric Cancer
03/14/2025
Lisa Kuhns, PhD, MD
Artificial intelligence (AI) is rapidly transforming the landscape of early gastric cancer (EGC) detection and treatment, offering promising solutions to improve diagnostic accuracy, treatment planning, and patient outcomes, according to an...
Artificial intelligence (AI) is rapidly transforming the landscape of early gastric cancer (EGC) detection and treatment, offering promising solutions to improve diagnostic accuracy, treatment planning, and patient outcomes, according to an...
Artificial intelligence (AI) is...
03/14/2025
Journal of Clinical Pathways
News
Oral JAK2 Inhibitor Offers a Viable Second-Line Treatment for Myelofibrosis, but Challenges Remain
03/13/2025
Lisa Kuhns, PhD, MD
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2...
03/13/2025
Journal of Clinical Pathways
News
Early Measurable Residual Disease Assessment Predicts Survival in Patients With Mantle Cell Lymphoma
03/12/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...
Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...
Patients with mantle cell...
03/12/2025
Journal of Clinical Pathways
News
Radiomics and AI Advance NSCLC Staging Precision
03/10/2025
Juliet Gallagher
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in...
03/10/2025
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Cost of Biosimilar Neutropenia Prophylaxis for Pancreatic Cancer
03/10/2022
True or False: Conversion to biosimilar pegfilgrastim-cbqv for chemotherapy-induced neutropenia and febrile neutropenia prophylaxis can generate cost-savings for patients with metastatic pancreatic cancer.
True or False: Conversion to biosimilar pegfilgrastim-cbqv for chemotherapy-induced neutropenia and febrile neutropenia prophylaxis can generate cost-savings for patients with metastatic pancreatic cancer.
True or False: Conversion to...
03/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Educating Patients With Pancreatic Cancer About Treatment Options
02/10/2022
True or False: Patients with pancreatic cancer infrequently hear about treatment complications and alternatives, while frequently hearing about logistics and potential outcomes.
True or False: Patients with pancreatic cancer infrequently hear about treatment complications and alternatives, while frequently hearing about logistics and potential outcomes.
True or False: Patients with...
02/10/2022
Journal of Clinical Pathways
Quiz
Quiz: What Drives Health Care Costs for Patients With Pancreatic Cancer?
09/11/2020
09/11/2020
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways
JCP January/February 2025

Current Issue

February 2025
Volume 11
Issue 1
Current Issue
Issue Archive

Special Reports

Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

FDA Approval
FDA Approves Irinotecan Liposome for First-Line Metastatic Pancreatic Adenocarcinoma
02/13/2024
Allison Casey
The US Food and Drug Association has granted approval to irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma in the first-line setting.
The US Food and Drug Association has granted approval to irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma in the first-line setting.
The US Food and Drug Association...
02/13/2024
Oncology
Quiz
Quiz: Cost of Biosimilar Neutropenia Prophylaxis for Pancreatic Cancer
03/10/2022
True or False: Conversion to biosimilar pegfilgrastim-cbqv for chemotherapy-induced neutropenia and febrile neutropenia prophylaxis can generate cost-savings for patients with metastatic pancreatic cancer.
True or False: Conversion to biosimilar pegfilgrastim-cbqv for chemotherapy-induced neutropenia and febrile neutropenia prophylaxis can generate cost-savings for patients with metastatic pancreatic cancer.
True or False: Conversion to...
03/10/2022
Journal of Clinical Pathways
News
Conversion to Biosimilar Neutropenia Prophylaxis Generates Cost-Savings and Provides Access to Pancreatic Cancer Treatment
02/11/2022
Janelle Bradley
Conversion to biosimilar pegfilgrastim-cbqv for neutropenia prophylaxis can generate potential cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.
Conversion to biosimilar pegfilgrastim-cbqv for neutropenia prophylaxis can generate potential cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.
Conversion to biosimilar...
02/11/2022
Journal of Clinical Pathways
Quiz
Quiz: Educating Patients With Pancreatic Cancer About Treatment Options
02/10/2022
True or False: Patients with pancreatic cancer infrequently hear about treatment complications and alternatives, while frequently hearing about logistics and potential outcomes.
True or False: Patients with pancreatic cancer infrequently hear about treatment complications and alternatives, while frequently hearing about logistics and potential outcomes.
True or False: Patients with...
02/10/2022
Journal of Clinical Pathways
News
Study Identifies Areas for Improvement in Educating Patients With Pancreatic Cancer About Treatment Options
11/03/2021
Marta Rybczynski
Study identifies key elements of information clinicians need to communicate to patients with pancreatic cancer to help make informed decisions regarding preoperative therapy.
Study identifies key elements of information clinicians need to communicate to patients with pancreatic cancer to help make informed decisions regarding preoperative therapy.
Study identifies key elements of...
11/03/2021
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use